ArticleNature communications2026
Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial.
Erratum issued Registry-linked trialAbstract readClinical Trial, Phase I
In one paragraph
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04117087 (Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer), which is not on this map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer
Who cites it
17 citing papers in PubMed.
- Review
- Therapeutic cancer vaccines: development, challenges, and future perspectives.Acta pharmacologica Sinica · 2026Review
- The Landmark Series: Mutation-Based Therapy of Pancreatic Cancer.Annals of surgical oncology · 2026Review
- Challenges and opportunities in combining radiotherapy and immunotherapy for localized pancreatic cancer.Nature reviews. Gastroenterology & hepatology · 2026Review
- mRNA-based therapeutics in lung Cancer: Mechanisms, applications, and translational challenges.Journal, genetic engineering & biotechnology · 2026Review
- Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma: from Tumor Biology to Biomarker-Guided Strategies.Current oncology reports · 2026Review
- Emerging Precision Therapeutic Strategies in Pancreatic Ductal Adenocarcinoma: KRAS Targeting, DDR Vulnerabilities, Immune Redirection, and Tumor Microenvironment Remodeling.Pharmaceutics · 2026Review
- First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.Cancer discovery · 2026Article
- Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond.Targeted oncology · 2026Review
- Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial.Nature communications · 2026Article
- Nucleic Acid Therapeutics for "Undruggable" Cancer Targets: Mechanisms, Challenges, and Prospects.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Immune interception in cancer: prioritizing vaccination in high-risk and premalignant settings.Frontiers in immunology · 2026Article
- Rethinking PDAC: from immunological silence to therapeutic opportunity.Frontiers in immunology · 2026Review
- Biomarker-driven immunotherapy and adoptive cell therapy in recurrent pancreatic ductal adenocarcinoma.Frontiers in medicine · 2026Review
- Structural quality-tier assessment for TCR-pMHC functional enrichment.Frontiers in immunology · 2026Article
- The role of inflammation in the immune evasion of KRas.Frontiers in immunology · 2026Review
- Profiling immunogenic neoantigen peptides elicited by personalized neoantigen vaccine in cancer patients.Frontiers in immunology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
39 authors.
Amanda L Huff *Johns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
S Daniel Haldar *Johns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Alexander A GirgisJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Hejia Henry WangJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-1836-7567
Ludmila DanilovaJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-2813-3094
Thatcher HeumannJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Maureen BergDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Yuxuan WangDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Lalitya AndalooriJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Alexei HernandezJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-6044-2631
Gabriella LongwayJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Benjamin BarrettJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Zirui ZhuJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Emily Davis-MarcisakJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Christopher ThoburnJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-7743-9183
James LeathermanJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-1721-2128
Sarah MitchellJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jae W LeeJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Daniel H ShuGreenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Maximillian F KonigDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-5045-5255
Brian J MogDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Janelle MontagneJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-8113-1373
Erin M CoyneJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-0393-6600
Katherine BeverJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Marina BarettiJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Mark YarchoanJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-4401-0748
Robert A AndersJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Luciane T KagoharaJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-1706-0950
Daniel LaheruJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-6646-0200
Amy M ThomasDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Jennifer DurhamJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Julie M NaurothJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jiayun LuJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Hao WangJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-6489-6940
Elana J FertigGreenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Won Jin HoJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-2644-5086
Nilofer S AzadJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Elizabeth M JaffeeJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ejaffee@jhmi.edu.ORCID http://orcid.org/0000-0003-3841-6549
Neeha ZaidiJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. nzaidi1@jhmi.edu.ORCID http://orcid.org/0000-0002-0094-0049
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6MTumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI THOMPSON, ELIZABETH D · 1993 to 2022
$54.6MONCOLOGY: CHEMOTHERAPY, IMMUNOLOGY, BIOLOGYT32CA009071 · NCI · JOHNS HOPKINS UNIVERSITY · PI Mary Y Armanios, Nilofer S. Azad · 1985 to 2026
$12.8MTransforming Human Pancreatic Cancer Into An Immunologic DiseaseP01CA247886 · NCI · JOHNS HOPKINS UNIVERSITY · PI JAFFEE, ELIZABETH M. · 2021 to 2025
$12.7MSingle-cell and imaging data integration software to spatially resolve the tumor microenvironmentU01CA253403 · NCI · JOHNS HOPKINS UNIVERSITY · PI FERTIG, ELANA · 2020 to 2022
$1.2MNeoantigen-Targeted Vaccines in Combination with Immune Checkpoint Inhibitors for Pancreatic CancerK08CA248624 · NCI · JOHNS HOPKINS UNIVERSITY · PI ZAIDI, NEEHA · 2021 to 2025
$1.1MComprehensive Analysis and Multi-Omics Data Integration for Cancer-Related StudiesR50CA243627 · NCI · JOHNS HOPKINS UNIVERSITY · PI Ludmila Danilova · 2019 to 2026
$975kStructural modeling of neoantigen presentation for rational design of heteroclitic neoepitope vaccinesF32CA271470 · NCI · JOHNS HOPKINS UNIVERSITY · PI HUFF, AMANDA L · 2022 to 2025
$156kLustgarten Foundation (Lustgarten Foundation for Pancreatic Cancer Research) PI: JaffeeNCI NIH HHS F32 CA271470NCI NIH HHS K08 CA248624NCI NIH HHS P01 CA247886NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA062924NCI NIH HHS R50 CA243627NCI NIH HHS T32 CA009071NCI NIH HHS U01 CA253403U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) F32CA271470-01U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) K08CA248624U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P01CA247886U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P50CA062924
Abstract
In this phase I study, we test a pooled synthetic long peptide vaccine targeting the six KRAS mutations (G12V, G12A, G12R, G12C, G12D, G13D) with ipilimumab and nivolumab in resected pancreatic adenocarcinoma. Co-primary endpoints include safety and maximal percent change of IFNγ-producing mutant KRAS T cell responses in the blood within 17 weeks. Secondary endpoints include disease-free survival, overall survival, and maximal percent change of IFNγ-producing mutant KRAS T cell responses at any time after vaccination. Vaccine-related adverse events are grade 1-2. 11/12 and 10/12 patients generate a significant increase in average T cell response to 6 mutant KRAS antigens and tumor-specific response, respectively. Immunophenotyping demonstrate Th1 CD4 central memory and effector memory T cells, and CD8 effector memory T cells at a lower frequency. The vaccine also generates cross-reactive T cells that recognize more than one mutant KRAS antigen. These findings support the safety and diverse anti-tumor immunity of mutant KRAS vaccines (NCT04117087).
Indexed as
AdenocarcinomaCancer VaccinesImmune Checkpoint InhibitorsPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)CD8-Positive T-LymphocytesFemaleHumansInterferon-gammaIpilimumabMaleMiddle AgedMutationProtein Subunit VaccinesCancer VaccinesImmune Checkpoint InhibitorsInterferon-gammaIpilimumabKRAS protein, humanProtein Subunit VaccinesProto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT04117087ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.